Thursday, May 24th, 2018 | 133 Views
BASF has launched Hepaxa, the first product in the US that can help patients manage steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD), by providing concentrated and pure eicosapentaenoic acid and docosahexaenoic acid, both characteristically deficient in NAFLD patients. It is manufactured using a patented purification technology to remove organic pollutants and other unwanted lipids which occur in fish oil-based products.
One such pollutant—specifically PCB 153—is harmful to NAFLD patients whose liver function is compromised, increasing the importance to avoid additional exposure to such components in traditional fish oil.
The product is available to NAFLD patients 10 years and older for use under medical supervision.